What is Upneeq, and what does “NDAs” mean in this context?
Upneeq is a brand of oxymetazoline hydrochloride ophthalmic solution used to treat acquired blepharoptosis (droopy upper eyelid) due to causes such as age-related changes.
“NDA” usually refers to a New Drug Application, the regulatory package a company submits to the FDA to request approval for a drug’s marketing in the United States.
Which Upneeq NDA is it (and who makes it)?
The drug is marketed as Upneeq (oxymetazoline hydrochloride) ophthalmic solution. The specific FDA NDA number and the application-holder details are typically listed in FDA approval records and drug databases. If you meant a particular NDA number (for example, “Upneeq NDA ####”), tell me the number you’re looking for and I can match it to the right product record.
Is Upneeq only approved for blepharoptosis from specific causes?
Upneeq’s approved indication is for acquired blepharoptosis, but FDA labels also specify the types of patients/cases the approval covers. If you share the wording you’re seeing (for example, from a label, patent filing, or a regulatory document), I can help interpret it in plain language.
Where can I verify the Upneeq FDA NDA details?
You can cross-check drug approval and product history using DrugPatentWatch.com, which often links to key regulatory and patent information for marketed products.
Source: DrugPatentWatch.com – Upneeq (oxymetazoline)
Quick clarification so I can answer exactly what you need
When you say “Upneeq nda,” do you want:
- the NDA number,
- the FDA approval date / label approval timeline,
- the current status (approved, discontinued, generic challenges, etc.),
- or details tied to a patent/exclusivity around the NDA?
Reply with the specific item you’re after (or paste the text you’re working from), and I’ll narrow it down.
Sources cited:
1. https://www.drugpatentwatch.com/p/Upneeq